Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Better Late Than Never: German Medtechs Make The Case For Practical MDR Improvements

Executive Summary

A regulatory system that cannot function as intended, even with an extra year for preparation, will become mandatory in the EU next week. German medtechs suggest a route forward.

You may also be interested in...



TEAM-NB Highlights Survey Figures Suggesting Massive 2024 Bulge In MDR Applications

Growing evidence demonstrates the one-year delay to the Medical Device Regulation, plus the expansion of the scope of products that could remain on the market beyond the MDR date of application, have simply pushed problems to 2024.

China Market Growth Spurs Siemens Healthineers To Restructure Asia Ops

Germany-headquartered Siemens Healthineers has uncoupled China from the rest of its Asia business to maximize opportunities in the world’s largest medtech market-in-waiting.

Putting The E In ESG: A Global Medtech’s Approach To Meeting The Climate Challenge

The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel